1)Collins CC, Volik SV, Lapuk AV, et al:Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. Mol Cancer Ther 11:775-783, 2012
2)Barbieri CE, Baca SC, Lawrence MS, et al:Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44:685-689, 2012
3)Grasso CS, Wu YM, Robinson DR, et al:The mutational landscape of lethal castration-resistant prostate cancer. Nature 12:239-243, 2012
4)Tomlins SA, Rhodes DR, Perner S, et al:Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-664, 2005
5)Wu C, Wyatt AW, Lapuk AV, et al:Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol 227:53-61, 2012
6)Beltran H, Yelensky R, Frampton GM, et al:Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 63:920-926, 2013
7)Watahiki A, Wang Y, Morris J, et al:MicroRNAs associated with metastatic prostate cancer. PLoS One 6:e24950, 2011
8)Chang KR, Chang CW, Tan SK, et al:A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J 31:2810-2823, 2012